FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for treating a patient suffering from a degenerative bone disease that can be characterised by loss of bone mineral density (BMD), wherein degenerative bone disorder is osteopenia or osteoporosis, comprising: formation of voids in localised area of intact bones of patient which had a degenerative bone disorder diagnosed by purification of degenerated bone material and, optionally, partial removal of a degenerated bone material intact before formation of cavities; and at least partially filling void material for bone regeneration comprising calcium sulphate able to be resorbable and induce bone formation sufficient to form new non-degenerative bone material throughout volume of at least a portion of void which is filled with material for bone regeneration, wherein material for bone regeneration is liquid during void filling.
EFFECT: invention allows for selective replacement of degenerated bone material in localised areas of bones with a bone regenerative material that is resorbed by body over time and replaced by newly generated bone material.
17 cl, 9 tbl, 34 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS FOR TREATING DEGENERATIVE BONE CONDITIONS | 2011 |
|
RU2668372C1 |
METHOD FOR PREVENTION OF LONG TUBULAR BONES FRACTURES IN OSTEOPOROSIS | 2021 |
|
RU2757959C1 |
DRUG PREPARATION USED FOR CARTILAGE DISEASES | 2006 |
|
RU2454999C2 |
METHOD OF REHABILITATION OF PATIENTS AFTER SURGICAL TREATMENT OF FRACTURE OF PROXIMAL FEMUR WITH UNDERLYING OSTEOPOROSIS | 2020 |
|
RU2740262C1 |
METHOD OF OSTEOPOROSIS CORRECTION IN TREATING UNUNITED FRACTURES AND FALSE JOINTS | 2010 |
|
RU2423983C1 |
METHOD OF ASSESSING MINERAL DENSITY OF BONE TISSUE IN PATIENTS WITH CHRONIC HEART FAILURE | 2013 |
|
RU2565833C2 |
PTH-CONTAINING THERAPEUTIC/PROPHILACTIC ANTI-OSTEOPOROSIS AGENT, CHARACTERISED BY WEEKLY INTRODUCTION OF PTH IN STANDARD DOSE OF 100-200 UNITS | 2010 |
|
RU2564894C2 |
COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF METABOLIC DISORDERS | 2010 |
|
RU2565020C2 |
COMPLEMENTED MATRIXES FOR TREATING BONE FRACTURES | 2006 |
|
RU2422172C2 |
MEDICINAL PREPARATION FOR TREATING OSTEONECROSIS AND FOR TREATING PATIENTS AT RISK OF OSTEONECROSIS DEVELOPMENT | 2001 |
|
RU2284821C2 |
Authors
Dates
2016-03-20—Published
2011-06-30—Filed